| A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19 DR Boulware, MF Pullen, AS Bangdiwala, KA Pastick, SM Lofgren, ... New England journal of medicine 383 (6), 517-525, 2020 | 1564 | 2020 |
| Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial CP Skipper, KA Pastick, NW Engen, AS Bangdiwala, M Abassi, ... Annals of internal medicine 173 (8), 623-631, 2020 | 640 | 2020 |
| Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19) KA Pastick, EC Okafor, F Wang, SM Lofgren, CP Skipper, MR Nicol, ... Open forum infectious diseases 7 (4), ofaa130, 2020 | 237 | 2020 |
| Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study J Rhein, BM Morawski, KH Hullsiek, HW Nabeta, R Kiggundu, L Tugume, ... The Lancet infectious diseases 16 (7), 809-818, 2016 | 181 | 2016 |
| Cryptococcal meningitis: diagnosis and management update M Abassi, DR Boulware, J Rhein Current tropical medicine reports 2, 90-99, 2015 | 180 | 2015 |
| Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial J Rhein, KH Hullsiek, L Tugume, E Nuwagira, E Mpoza, EE Evans, ... The Lancet infectious diseases 19 (8), 843-851, 2019 | 100 | 2019 |
| Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized … MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ... Jama 327 (5), 432-441, 2022 | 99 | 2022 |
| Symptoms of COVID-19 outpatients in the United States MF Pullen, CP Skipper, KH Hullsiek, AS Bangdiwala, KA Pastick, ... Open forum infectious diseases 7 (7), ofaa271, 2020 | 72 | 2020 |
| Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda M Abassi, BM Morawski, G Nakigozi, N Nakasujja, X Kong, DB Meya, ... Journal of neurovirology 23, 369-375, 2017 | 66 | 2017 |
| Detrimental outcomes of unmasking cryptococcal meningitis with recent ART initiation J Rhein, KH Hullsiek, EE Evans, L Tugume, E Nuwagira, ... Open forum infectious diseases 5 (8), ofy122, 2018 | 59 | 2018 |
| Safety of hydroxychloroquine among outpatient clinical trial participants for COVID-19 SM Lofgren, MR Nicol, AS Bangdiwala, KA Pastick, EC Okafor, ... Open forum infectious diseases 7 (11), ofaa500, 2020 | 58 | 2020 |
| HIV-associated cryptococcal meningitis occurring at relatively higher CD4 counts L Tugume, J Rhein, KH Hullsiek, E Mpoza, R Kiggundu, ... The Journal of infectious diseases 219 (6), 877-883, 2019 | 50 | 2019 |
| Emerging fluconazole resistance: implications for the management of cryptococcal meningitis E Mpoza, J Rhein, M Abassi Medical mycology case reports 19, 30-32, 2018 | 44 | 2018 |
| Phase I EnACT trial of the safety and tolerability of a novel oral formulation of amphotericin B CP Skipper, M Atukunda, A Stadelman, NW Engen, AS Bangdiwala, ... Antimicrobial agents and chemotherapy 64 (10), 10.1128/aac. 00838-20, 2020 | 42 | 2020 |
| Diagnosis and management of central nervous system cryptococcal infections in HIV-infected adults C Skipper, M Abassi, DR Boulware Journal of Fungi 5 (3), 65, 2019 | 39 | 2019 |
| Symptomatic cryptococcal antigenemia presenting as early cryptococcal meningitis with negative cerebral spinal fluid analysis K Ssebambulidde, AS Bangdiwala, R Kwizera, TK Kandole, L Tugume, ... Clinical infectious diseases 68 (12), 2094-2098, 2019 | 34 | 2019 |
| Evaluation of a point-of-care immunoassay test kit ‘StrongStep’for cryptococcal antigen detection E Mpoza, L Mukaremera, DA Kundura, A Akampurira, T Luggya, ... PLoS One 13 (1), e0190652, 2018 | 31 | 2018 |
| Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial SA Lother, M Abassi, A Agostinis, AS Bangdiwala, MP Cheng, G Drobot, ... Canadian Journal of Anaesthesia 67 (9), 1201, 2020 | 28 | 2020 |
| Minimum Inhibitory Concentration Distribution of Fluconazole Against Cryptococcus Species and the Fluconazole Exposure Prediction Model S Chesdachai, R Rajasingham, MR Nicol, DB Meya, F Bongomin, ... Open forum infectious diseases 6 (10), ofz369, 2019 | 26 | 2019 |
| Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis L Tugume, BM Morawski, M Abassi, NC Bahr, R Kiggundu, HW Nabeta, ... HIV medicine 18 (1), 13-20, 2017 | 24 | 2017 |
